Compare Incyte Corporation (INCY) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Li Auto Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Li Auto Inc trades at $12.62 (market cap $12.28B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| INCY | LI | |
|---|---|---|
Market Cap | $24.54B | $12.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $26.69 |
52-Week Low | $81.61 | $11.74 |
Enterprise Value | $20.04B | $1.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Li Auto (LI) trades at $12.84, down 0.85% on the day, with bearish technical signals and mixed earnings performance. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle launches including the Li L6 and L8 aim to boost deliveries amid intense Chinese EV competition.
While analyst consensus suggests moderate upside to $14.80 price target, significant risks include declining profitability, negative cash flow trends, and competitive pressures in China's EV market. The stock faces headwinds from execution challenges and macroeconomic uncertainties affecting the auto sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
